Navigation Links
Sinovac Reports Unaudited Third Quarter 2009 Financial Results
Date:11/15/2009

commercialize our H1N1 and H5N1 vaccines. We recorded revenues from doses sold in China and Macau. Given our strong product mix, we were able to maintain our gross profit margin in excess of 80%. With the continued execution of our commercialization strategy, we remain on track to exceed the previously projected full year 2009 revenue range of $55 million to $60 million."

Market Overview

The People's Republic of China (PRC) government's expansion program of publicly funded inoculations has driven increased demand for Sinovac's principal product, Healive. Although the gross margin on public sales is lower than on private sales, Sinovac expects to realize volume-related offsetting cost savings and efficiencies.

In the current year, Sinovac expects to generate significant revenues from the sale of its H1N1 vaccine; this is expected to be a short-term initiative that will extend through to the end of the influenza season in the spring of 2010. These sales are not expected to be recurring, but demonstrate the Company's ability to develop, manufacture and distribute vaccines on short notice.

At the same time, the outbreak of H1N1 pandemic flu appears to have increased the demand for seasonal flu vaccines. It is expected that increasing sales of Anflu will benefit the company over the long-term.

Financial Review for Three Months Ended September 30, 2009

During the third quarter of 2009, sales were $21.2 million, up 142% from $8.7 million in the third quarter of 2008. During the third quarter of 2009, Sinovac's unit dose sales were:

    Three months ended September 30,               2009              2008
                                               (000 doses)       (000 doses)
                                               -----------       -----------
    Healive                                         989             1,087

    Bilive                                          215 
'/>"/>
SOURCE Sinovac Biotech Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
2. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
3. Sinovac to Present at 2009 UBS Global Life Sciences Conference
4. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
5. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
6. Sinovac Obtains Production License for H1N1 Vaccine
7. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
8. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
9. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
10. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
11. Sinovac Adjourns 2008 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Corporation,s (Amex: ETC ) ("ETC" or the ... contract with the Netherlands,Institute for Safety, NIFV, to ... Simulator for Aircraft Rescue Fire Fighting., The ... military helicopter,scenario consisting of AH-64 Apache helicopters parked ...
... FRANCISCO, Calif., Nov. 3 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... enrollment,in a large Phase II clinical trial ... inhibitor anticoagulant, for stroke prevention in patients ...
... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today announced it has started,a Phase ... enzyme,(rHuPH20) co-formulations with Humulin(R) R (regular insulin ... Type 1 diabetic,patients. This study is designed ...
Cached Biology Technology:Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 2Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 2Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 4Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4
(Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
(Date:8/28/2014)... pleased to announce the selection of Dr. Fred Baxendale ... acknowledges those who have served ESA for at least ... the Society that has reached an extraordinary level. Candidates ... Board and then voted on by the ESA membership. ... at Entomology 2014, ESA,s Annual Meeting in Portland, Oregon ...
(Date:8/28/2014)... news release is available in German . ... water fish, owes its name to a striking pattern of ... types, black cells, reflective silvery cells, and yellow cells emerge ... and arrange as a multilayered mosaic to compose the characteristic ... three cell types have to interact to form proper stripes, ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... in German . , Researchers at the Max ... the Czech Academy of Sciences in Prague have developed a new ... acids, amino acids and other organic substances from plant or animal ... liter -- is sufficient to identify certain blood related metabolites. ...
... of fishing gear could help the world,s coral reefs and their ... team of scientists led by Dr Josh Cinner of the ARC ... has proposed that bans on fishing gear - like spear guns, ... in the recovery of reefs and fish populations hard hit by ...
... Although worlds apart, the way fish learn could be ... a new research study. A common species of fish ... nine-spined stickleback, could be the first animal shown to exhibit ... compare the behaviour of other sticklebacks with their own experience ...
Cached Biology News:An easy way to find a needle in a haystack by removing the haystack 2An easy way to find a needle in a haystack by removing the haystack 3Gear bans 'can help save reefs' 2Gear bans 'can help save reefs' 3Common fish species has 'human' ability to learn 2Common fish species has 'human' ability to learn 3
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Request Info...
MOUSE ANTI HUMAN FACTOR I...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Biology Products: